Navigation Links
Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
Date:12/7/2007

nd health plans covering over 50 percent of U.S. insured lives provide reimbursement for Oncotype DX through contracts, agreements and policy decisions. The American Society of Clinical Oncologists (ASCO) recommends the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test service, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

NOTE: Genomic Health, the Genomic Health logo, Oncotype, Oncotype DX and Recurrence Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
9. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
10. Tone Deafness Explained, from the Harvard Health Letter
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
(Date:11/26/2014)... WASHINGTON and NEW YORK ... 2014 As the leading distributor of market ... a new research report by IQ4I Research and Consultancy ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast ...
(Date:11/26/2014)... , Nov. 25, 2014 Reinforcing its ... Philips (NYSE: PHG AEX: PHIA) ... Drug Administration (FDA) for its IQon Spectral CT ... This first-of-its kind technology adds a new dimension to ... the ability to characterize structures based on their material ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
... Water Street Healthcare Partners , a strategic ... today that it has acquired MarketLab, Inc. ... in the specialty healthcare distribution sector.  The acquisition expands ... in distribution, life sciences, medical devices and services to ...
... Colo., June 27, 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: ... "Company"), a company that discovers and develops new uses ... today announced results of its phase III, randomized, double-blind, ... of two doses of Zertane™ for the treatment of ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction 2Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction 3Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction 4Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction 5
(Date:11/27/2014)... York, New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated ... Liebhard LLP reports. , Documents recently updated ... 1,079 records included in the state proceeding, all ... schizophrenia, bipolar disorder and other psychiatric conditions. Many ...
(Date:11/27/2014)... Most babies and young children don,t need medicines if ... Administration says. Over-the-counter (OTC) cold and cough medicine ... because they could cause serious and potentially deadly side ... three colds a year, but children get them more ... to give them pain relievers, decongestants and other medicines, ...
(Date:11/27/2014)... meals can pose a challenge for people who have ... Many traditional Thanksgiving dishes -- such as turkey, corn, ... "when it comes to pies, stuffing, gravy, etc., gluten-free ... director of the Gluten and Allergic Digestive Disorders program ... said in a center news release. "For those ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... Now that Thanksgiving is finally here ... Emassagechair.com has announced its eagerly awaited, once ... , Negotiating on behalf of their customers, and drawing ... Emassagechair.com has generated significant buzz in the industry with ... yet. , Shoppers are excited for significant savings available ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4
... News) -- Statins, a class of cholesterol-lowering drugs that includes ... had a certain kind of stroke with unknown cause, a ... young people, and it,s even more uncommon for them to ... the Aug. 2 issue of the journal Neurology , ...
... fecal occult blood test (iFOBT) is effective for predicting ... upper gastrointestinal (GI) tract, confirms a study in ... link only) http://www.cmaj.ca/site/embargo/cmaj101248.pdf . The immunochemical fecal ... screen for bleeding without symptoms in the lower GI ...
... of 1 percent of the microbes that live in the colon, ... gut are fundamental to colon health. In a new study ... where they live and how abundant they are in different parts ... International Society for Microbial Ecology Journal . This is ...
... A novel therapy that reduces elevated blood levels of a ... of pregnancy, may someday address the therapeutic dilemma posed by ... the dangers that early delivery poses to an immature fetus. ... Circulation , a team of U.S. and German researchers ...
... a lower socioeconomic status neighborhood are more likely to ... more affluent neighborhoods, according to a new RAND Corporation study. ... of Public Health , is the largest of its type ... with lower cognitive function. The study found that potential ...
... of Vanderbilt University was awarded a $25,000 grant from ... research in abnormal BCL6 overexpression, which occurs in a ... Vanderbilt University have obtained drugs that inhibit HDAC3another epigenetic ... cancer. Scientists believe that by eliminating BCL6, they can ...
Cached Medicine News:Health News:Statins May Help Heart in Some Young Stroke Patients 2Health News:Noninvasive fecal occult blood test effective screen for lower GI tract lesions 2Health News:Researchers map minority microbes in the colon 2Health News:Researchers map minority microbes in the colon 3Health News:Pilot study suggests new approach to treat preeclampsia 2Health News:Pilot study suggests new approach to treat preeclampsia 3Health News:Neighborhood status influences older women's cognitive function, study finds 2
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
... CVMstat® provides leading ... of topics involving all ... including sections on diagnosis ... arterial and venous disease. ...
... to the management of common ... a response from leading experts ... more common, and often poorly ... It is a "how-to" guide ...
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
Medicine Products: